Referências Bibliográficas

1. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239-244.

2. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis. 1993;167:1247-1251.

3. Abi-Said D, Anaissie E, Uzon O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24:1122-1128.

4. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994;38:1422-1424.

5. Pappas PG, Rex JH, Hammill RJ, et al. NIAID MSG Candidiasis Subproject. Current trends in nosocomial candidemia: results of a large multicenter study. 35th Annual Meeting of the Infectious Diseases Society of America; 1997. Abstract 13.

6. Weems JJ Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis. 1992;14:756-766.

7. Berrouane YF, Hollis RJ, Pfaller MA. Strain variation among and antifungal susceptibilities of isolates of Candida krusei. J Clin Microbiol.1996;34:1856-1858.

8. Sobel JD, McKinsey D, Kauffman C, et al. Asymptomatic candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis. 1999;30:19-24.

9. Berenguer J, Buck M, Witebsky F, et al. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis. 1993;17:103-109.

10. Morrison VA, Haake RJ, Weisdorf DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med. 1994;96:497-503.

11. Carpenter CF, Subramanian AK. Images in clinical medicine. Cutaneous zygomycosis (mucormycosis). N Engl J Med. 1999;16:1891.

12. Krcmery V Jr, Jesenska Z, Spanik S, et al. Fungemia due to Fusarium spp. in cancer patients.J Hosp Infect. 1997;36:223-228.

13. Bushelman SJ, Callen JP, Roth DN, et al. Disseminated Fusarium solani infection. J Am Acad Dermatol. 1995;32(2 Pt 2):346-351.

14. Wilhelmus KR, Robinson NM, Font RA, et al. Fungal keratitis in contact lens wearers. Am J Ophthalmol. 1988;106:708-714.

15. Pfaller MA. Epidemiology of candidiasis. J Hosp Infect 1995;30(suppl):329-338.

16. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiolo Rev. 1996;9:499-511.

17. Richards MJ, Edward JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27:887-892.

18. Abbasi S, Shenep JL, Hughes WT, et al. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis. 1999;29:1210-1219.

19. Wallace JM, Lim R, Browdy BL, et al. Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest. 1998;114:131-137.

20. Krcmery V Jr, Mateicka F, Kunova A, et al. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazole. Support Care Center. 1999;7:39-43.

21. Pagano L, Antinori A, Ammassari A, et al. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors, and outcome of 76 episodes. Eur J Haematol. 1999;63:77-85.

22. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a retrospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28:1070-1079.

23. Hung CC, Chen YC, Chang SC, et al. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc. 1996;95:19-28.

24. Iwen PC, Reed EC, Armitage JO, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol. 1993;14:131-139.

25. Patterson TF, Kirkpatrick WR, White M, et al. Therapy of invasive aspergillosis: Disease spectrum, treatment practices, and outcomes. Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996; New Orleans, La.

26. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med. 1996;100:171-178.

27. Blum U, Windfuhr M, Buitrago-Tellez C, et al. Invasive pulmonary aspergillosis. MRI, CT, and plain radiographic findings and their contribution for early diagnosis. Chest. 1994;106:1156-1161.

28. Diederich S, Scadeng M, Dennis C, et al. Aspergillus infection of the respiratory tract after lung transplantation: chest radiographic and CT findings. Eur Radiol. 1998;8:306-312.

29. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139-147.

30. Patterson TF, Miniter P, Patterson JE. Aspergillus antigen detection in the diagnosis of invasive aspergillosis. J Infect Dis. 1995;171:1553-1558.

31. Yamakami Y, Hashimoto A, Yamagata E, et al. Evaluation of PCR for detection of DNA specific for Aspergillus species in sera of patients with various forms of pulmonary aspergillosis. J Clin Microbiol. 1998;36:3619-3623.

32. de Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia. 1996;10 Suppl 2:s93-96.

33. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764-771.

34. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103:205-212.

35. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383-1396.

36. Otsubo T, Maesaki S, Hossain MA, et al. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. Antimicrob Agents Chemother. 1999;43:471-475.

37. Cicogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother. 1997;41:259-261.

38. Allende MC, Lee JW, Francis P, et al. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary asperigillosis. Antimicrob Agents Chemother. 1994;38:518-522.

39. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999;29:1402-1407.

40. van't Wout JW. Therapy of systemic mycoses in neutropenic patients using itraconazole. A comparative, randomized study with amphotericin B. Med Klin. 1991;86(suppl 1):11-13.

41. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994;330:263-272.

42. Caillot D, Basaris H, Seifert WF, et a. Efficacy, safety, and pharmacokinetics of intravenous followed by oral itraconazole in patients with invasive pulmonary aspergillosis. Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 1646.

43. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis. 1999;35:19-25.

44. Fratti RA, Belanger PH, Sanati H. The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells. J Chemother. 1998;10:7-16.